Osiris Therapeutics, Inc.  

(Public, NASDAQ:OSIR)   Watch this stock  
Find more results for OSIR
+0.01 (0.06%)
Jan 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.19 - 17.07
52 week 11.80 - 17.60
Open 16.54
Vol / Avg. 112,294.00/140,270.00
Mkt cap 579.67M
P/E     -
Div/yield     -
EPS -0.08
Shares 34.32M
Beta 1.12
Inst. own 39%
Mar 3, 2015
Q4 2014 Osiris Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 2, 2014
Osiris Therapeutics Inc at Piper Jaffray Healthcare Conference
Nov 7, 2014
Q3 2014 Osiris Therapeutics Inc Earnings Release
Nov 7, 2014
Q3 2014 Osiris Therapeutics Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 4.13% -4.50%
Operating margin 7.09% -11.65%
EBITD margin - -9.24%
Return on average assets 3.15% -1.64%
Return on average equity 3.50% -1.87%
Employees 70 -
CDP Score - -


7015 Albert Einstein Drive
United States - Map
+1-443-5451800 (Phone)
+1-443-5451701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Osiris Therapeutics, Inc. (Osiris) is a stem cell company. The Company is an integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products. The Company has developed an intellectual property portfolio to protect its technology and commercial interests. Its Biosurgery business works to harness the ability of cells and constructs to promote the body's natural healing with the goals of improving surgical outcomes and offering better treatment options for patients and physicians. The Company´┐Żs Biosurgery products includes Grafix, Ovation, Cartiform, and OvationOS, each of which it developed and manufacture. Grafix is a three-dimensional placental tissue matrix for use as a wound covering for application directly to acute and chronic wounds, including diabetic foot ulcers, venous leg ulcers, and burns.

Officers and directors

Peter Friedli Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Lode Debrabandere Ph.D. President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Philip R. Jacoby Jr. Chief Financial Officer, Treasurer, Corporate Secretary
Age: 61
Bio & Compensation  - Reuters
Gregory I. Law Principal Accounting Officer, Vice President - Finance
Age: 48
Bio & Compensation  - Reuters
Jonathan Mark Hopper Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Felix Gutzwiller M.D., Ph.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Hans Klingemann M.D., Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Jay M. Moyes Independent Director
Age: 60
Bio & Compensation  - Reuters